Judge Finds Novo's Prandin Patent Invalid
A federal judge Wednesday found the patent for Novo Nordisk A/S diabetes drug Prandin invalid because of obviousness and unenforceable due to inequitable conduct, paving the way for Caraco Pharmaceutical Laboratories...To view the full article, register now.
Already a subscriber? Click here to view full article